# Irinotecan in Treating Patients With Recurrent Malignant Glioma

> **NCT00003301** · PHASE1,PHASE2 · COMPLETED · sponsor: **New Approaches to Brain Tumor Therapy Consortium**

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00003301
- **Lead sponsor:** New Approaches to Brain Tumor Therapy Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-07
- **Primary completion:** —
- **Final completion:** 2004-04
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003301, "Irinotecan in Treating Patients With Recurrent Malignant Glioma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00003301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*